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Abstract
Some food-derived peptides possess bioactive properties, and may affect health positively.
For example, the C-terminal lacto-tri-peptides Ile-Pro-Pro (IPP), Leu-Pro-Pro (LPP) and Val-
Pro-Pro (VPP) (together named here XPP) are described to lower blood pressure. The bio-
activity depends on their availability at the site of action. Quantitative trans-organ availability/
kinetic measurements will provide more insight in C-terminal tri-peptides behavior in the
body. We hypothesize that the composition of the meal will modify their systemic availability.
We studied trans-organ XPP fluxes in catheterized pigs (25 kg; n=10) to determine systemic
and portal availability, as well as renal and hepatic uptake of a water-based single dose of
synthetic XPP and a XPP containing protein matrix (casein hydrolyte, CasH). In a second
experiment (n=10), we compared the CasH-containing protein matrix with a CasH-containing
meal matrix and the modifying effects of macronutrients in a meal on the availability (high
carbohydrates, low quality protein, high fat, and fiber). Portal availability of synthetic XPP
was 0.08 ± 0.01% of intake and increased when a protein matrix was present (respectively
3.1, 1.8 and 83 times for IPP, LPP and VPP). Difference between individual XPP was proba-
bly due to release from longer peptides. CasH prolonged portal bioavailability with 18 min
(absorption half-life, synthetic XPP: 15 ± 2 min, CasH: 33 ± 3 min, p<0.0001) and increased
systemic elimination with 20 min (synthetic XPP: 12 ± 2 min; CasH: 32 ± 3 min, p<0.0001).
Subsequent renal and hepatic uptake is about 75% of the portal release. A meal containing
CasH, increased portal 1.8 and systemic bioavailability 1.2 times. Low protein quality and
fiber increased XPP systemic bioavailability further (respectively 1.5 and 1.4 times). We con-
clude that the amount and quality of the protein, and the presence of fiber in a meal, are the
main factors that increase the systemic bioavailability of food-derived XPP.
Introduction
In the recent years our understanding of potential food-derived bioactive peptides and their
potential health benefits advanced [1,2], mainly on the role of bioactive peptides from milk.
For instance, the effects on blood pressure of the lacto-tri-peptides Isoleucine-Proline-Proline
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(IPP) and Valine-Proline-Proline (VPP) is described in animal [3] and human studies [4–12].
The hypothesized working mechanism of these peptides is inhibition of the angiotensin I con-
verting (ACE) enzyme [4] and is related to the presence of a proline residue on the C-terminal
of the lacto-tri-peptides [13]. Animal and human studies also suggest that IPP and VPP reduce
arterial stiffness and improve endothelial activity [14,15].
The beneficial effects of food-derived bioactive peptides depend on availability on the site of
action. For instance, to exert a potential ACE inhibition effect after oral intake of the lacto-tri-
peptides, the peptides have to reach the cardiovascular system in an active form [16]. Metabolic
active organs like the intestine, liver, and kidney play a major role in the availability. Fluxes of
these peptides through those organs are likely to be dependent on the fluxes of other macronu-
trients, especially proteins and amino acids [17–22]. No fundamental knowledge of quantita-
tive organ flux data are available for food-derived bioactive lacto-tri-peptides to get more
insight in the behavior of those peptides in the body [23]. Therefore, the main aim of the pres-
ent study is to collect quantitative data about how much food-derived bioactive lacto-tri-
peptides is absorbed and released to the portal system, the role of kidney and liver and their
effect on the systemic availability under different nutritional conditions. We studied IPP, VPP
and LPP (Leucine-Proline-Proline), named together as XPP as model for C-terminal proline
containing food-derived peptides in general, because they are relatively resistant against break-
down in the gastro-intestinal tract and therefore expected to be similar in their kinetics [3,24].
Previously, we found that the systemic bioavailability of a single dose of synthetic XPP,
when given orally as a single dose, was less than 0.1% [25] with a half-life maximum at 15 min.
In the present study, we hypothesize that dietary composition modifications improve absorp-
tion kinetics of XPPs and thus their bioavailability.
Therefore, we studied trans-organ XPP fluxes in catheterized pigs to determine the effect
of a protein matrix on the XPP systemic and portal availability, renal and hepatic uptake
using a XPP containing casein hydrolyte (CasH). Casein is the main lacto-protein that is rich
of encrypted XPP’s (www.genome.jp). This, in contrast with the lacto-protein whey or a non-
milk protein soy with no encrypted XPP’s. The studied CasH is rich of liberated IPP and LPP,
produced by using enzymes including a specific prolyl-endoprotease [26]. This CasH is
proven to have ACE inhibitory potential [12] and has a faster digestion and absorption rate
[27] than casein, which potentially relates to the maximally available systemic XPP concentra-
tions. In a second experiment, we studied the potential effect on XPP availability when the
XPP containing CasH was added to a meal and studied the potential modifying effects of
macro-nutrients (high carbohydrates, low quality protein, high fat, and fiber) in the meal.
Quantification of intestinal absorption kinetics of XPP and the role of liver and kidney is not
possible in humans, therefore we measured the transorgan XPP fluxes in conscious multi-
catheterized pigs [28,29] as the gastro-intestinal tract of the pig is comparable with that of
humans [30–32].
The quantitative results of the present study are important as crucial fundamental informa-
tion for the development of therapies with bioactive peptides.
Material and Methods
Animals
For each study, we used 10 pathogen-free, female piglets (Dutch landrace x Yorkshire; 8–12
weeks of age; 25.2 ± 1.1 kg body weight) that were adapted to individual housing in straw con-
taining pens (2 x 3 m) with 12h day-night cycle and an environmental temperature of 23°C
one week before surgery. Catheters for blood sampling were placed during surgery [28] under
isoflurane (2% mixture with oxygen) anesthesia and flunixin meglumine (50 mg/25 kg bw)
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analgesia, in the abdominal aorta, the portal vein, the hepatic vein, and the renal vein. Catheters
for infusions of post-operative medication or para-aminohippuric acid solution (PAH; flow
measurements) were placed in the central vein and splenic vein and for gastric administration
a gastric catheter. We checked the position of the catheter tips with X-ray during surgery using
fluoroscopy and an iodine containing contrast solution.
During the recovery period (7–10 days), twice daily, we and the assigned veterinarian of the
animal care facility monitored the animals for general behavior, body temperature, food intake,
body weight and catheter patency and administered buprenorphine (0.03mg/kg) analgesia,
intra-venous, twice daily on day 1–4 and when needed. Animals were accustomed to a small
movable cage (0.9 x 0.5 x 0.3 m) to perform the experiments. At all times, animals would be
euthanized with 195 mg/kg bw pentobarbital sodium and 25 mg/kg bw phenytoin sulfate,
intra-venous, if imminent death is expected.
Ethics Statement. The animal ethics committee of Maastricht University, The Nether-
lands approved the studies: 2004–101. We performed the surgery under isoflurane anesthesia,
and all efforts were made to minimize suffering. The researchers and the assigned veterinarian
of the animal care facility monitored the anesthesia and recovery closely.
Experimental protocol
Study 1. After a postoperative recovery period of 7–10 days, we conducted five test days
with XPP mixtures according to a Williams cross-over design [33] with a minimum of 2 days
(washout) between the test days. One intra-venous administered IPP, LPP and VPP mixture
(data previously published [25]) and four intra-gastric administered XPP mixtures were stud-
ied (Table 1). We studied a control solution (Control-group) without XPP, but iso-ionogenic
to the other mixtures for sodium, potassium and calcium ions, to determine potential occur-
ring endogenous XPP fluxes. We gave a water-based matrix with comparable amounts of IPP,
LPP and VPP (XPP-group) for comparison with a protein based XPP mixture (casein hydro-
lyte, CasH-group). The CasH contained known amounts of free XPP with a C-terminal proline.
We gave a XPP spiked protein matrix (CasH+XPP group) to evaluate the influence of a protein
matrix on individual XPP’s. In the present study, we only will discuss the data of the four intra-
Table 1. Composition of test mixtures—Study 1.
Substance Unit Control XPP1 CasH2 CasH2+XPP1
IPP μmol/kg bw 0.0 12.3 10.7 23.0
LPP μmol/kg bw 0.0 12.3 32.9 45.2
VPP μmol/kg bw 0.0 12.8 0.62 13.4
Total XPP 3 μmol/kg bw 0.0 37.4 44.2 81.6
Protein mg/kg bw 0.0 0.0 648 648
Sodium mM 3.01 3.01 3.01 3.01
Potassium mM 71.14 71.14 71.14 71.14
Calcium mM 1.96 1.96 1.96 1.96
Phosphate mM 71.1 71.1 102.9 102.9
1) Chemical purities of the IPP, LPP, and VPP synthetic products were 93.4, 95.0 and 98.7%, respectively (Bachem, Weil am Rhein, Switzerland).
2) The given amounts of tri-peptides isoleucine-proline-proline (IPP), leucine-proline-proline (LPP), valine-proline-proline (VPP) in the casein hydrolysate
(CasH, Casimax, DSM Food Specialties, Delft, The Netherlands). The casein hydrolysate contained 57% protein with 5.4, 16.5 and 0.3 mg/g protein of
LPP, LPP and VPP, respectively.
3) Total XPP = total amount of IPP, LPP and VPP.
doi:10.1371/journal.pone.0130638.t001
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gastric administered XPP. We administered these mixtures as a single bolus with an end vol-
ume of 14 ml/kg body weight and temperature of 37°C.
Study 2. After a postoperative recovery period of 7–10 days, we conducted six test days
with CasH interventions according to a Williams cross-over design [33] with a minimum of 2
days (washout) between the test days. We compared a CasH supplemented meal matrix (Basal-
group) to a CasH only protein matrix (CasH2-group). We also compared four other CasH sup-
plemented meals with low protein quality (LQprot-group), high carbohydrate (hCHO-group),
high fat (hFat-group) and fiber containing Basal meal (Fiber-group) to Basal to evaluate the
influence of macronutrients (Table 2). The Basal meal contains a ratio of 25:50:25 En% of the
macronutrients protein, carbohydrates and fat. All meals were iso-caloric (30% of daily intake:
37.2 kcal/kg bodyweight) and composed by Research Diet Services (Wijk bij Duurstede, The
Netherlands). The protein fraction in the meals was a high quality whey protein isolate, while
in the low quality protein diet a soy protein isolate that had 24% less essential amino acids. We
gave all meals intra-gastric as a single bolus with an end volume of 24 ml/kg bodyweight and
37°C and observed for 360 min.
Sixteen hours before each test day, we removed food. Plasma flow determination started 1h
before feeding (t = 0) and continued throughout the experiment by a primed-continuous infu-
sion of para-aminohippuric acid through the splenic infusion catheter. At steady state concen-
trations of PAH (1 hour [28]), we took blood samples from the arterial, portal, hepatic, and
renal vein. We gave the liquid test mixture or meal via the gastric catheter within 5 min. Subse-
quently, we took blood samples (1.5 ml/sample) in study 1 from the arterial, portal, hepatic
and renal catheter at T = 1, 3, 5, 7, 9, 12.5, 17.5, 25, 30, 40, 50, 60 and 90 min; in study 2 from
the arterial and portal catheter at T = 10, 20, 40, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330
and 360 min.
Table 2. Composition of test meals—Study 2.
Nutrient Units CasH2 Basal LQprot hCHO hFat Fiber
Meal Whey protein Energy % 0 25 0 25 25 25
Soy protein Energy % 0 0 25 0 0 0
CHO Energy % 0 50 50 65 25 50
Fat Energy % 0 25 25 10 50 25
Total energy intake kcal/kg bw 0 37.2 37.2 37.2 37.2 37.2
Whey protein 1 g/kg bw 0 2.32 0 2.32 2.32 2.32
Soy protein 1 g/kg bw 0 0 2.32 0 0 0
CHO 2 g/kg bw 0 4.64 4.64 6.04 2.32 4.64
Fat 3 g/kg bw 0 1.04 1.04 0.42 2.07 1.04
Supplement Casein hydrolysate 4 g/kg bw 0.73 0.73 0.73 0.73 0.73 0.73
Fiber 5 g/kg bw 0 0 0 0 0 0.18
Gross weight g/kg bw 1.28 9.80 9.94 10.7 8.32 9.99
End Volume ml/kg bw 24 24 24 24 24 24
1): Indicated is the amount of protein supplied by the isolates.
2): CHO: maize starch, sucrose and glucose in the weight ratio 2:1:1.
3): Fat: soybean oil and sunflower oil in the weight ratio 4:1.
4) The casein hydrolysate product (Casimax, DSM Food Specialties, Delft, The Netherlands) contained 57% protein with 5.4, 16.5 and 0.3 mg/g protein
LPP, LPP and VPP, respectively.
5) Fiber: modified citrus pectin.
doi:10.1371/journal.pone.0130638.t002
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Sample processing
Directly after collection in Lithium-Heparin tubes, we placed the blood samples on ice. We
processed all blood samples within 1 hour after collection to ensure stability of the substances.
We centrifuged at 4°C for 15 min at 3000 g to obtain plasma. For PAH concentration determi-
nations we added 40 μl of 50% w/v Tri-chloroacetic acid solution (TCA) to 400 μl of plasma
and mixed. For XPP analyses, we added 10 μl of 10% w/v tri-fluoroacetic acid (TFA) to 500 μl
plasma and mixed. We froze the samples in liquid nitrogen and stored at -80°C until further
analysis. We took samples from the PAH infusion solutions and the test mixtures.
Biochemical analyses
We analyzed the plasma samples and test mixtures for the peptides IPP, LPP and VPP (XPP)
content [25,34]. We added 50 μl internal standard solution, containing U-13C-IPP,
U-13C-VPP, and U-13C-LPP to homogenized plasma (20 μl) and 480 μl water. After mixing,
we acidified this aliquot with tri-fluoroacetic acid to pH<3. We removed proteins by heating
the aliquot at 95°C for 2 min, followed by centrifugation at 22,000 g for 30 min at 15°C. We
quantified the XPP’s in the supernatant with LC-MS (Quattro Ultima, Waters, Milford, MA,
USA). The detection limit of quantification of this procedure was 0.28, 0.28, and 0.71 nM for
IPP, LPP, and VPP respectively.
We tested samples of test mixtures by mixing 100 μl of the sample with 100 μl of a standard
solution of universally 13C- labeled IPP [U-13C-IPP] and VPP [U-13C-VPP] (Biopeptide Co.,
San Diego, CA, USA). Then we mixed for 1 min, followed by centrifugation for 20 min at
16,000 x g at room temperature. This procedure allows determination of XPPs in the test mix-
tures between 1.9 and 123 μM.
We analyzed in a pilot set of plasma samples from Study 1, the occurrence of di-peptides
with proline (Proline-Proline (PP), leucine (LP), valine (VP), isoleucine (IP)). We determined
di-peptide concentrations with an automated LC-ESI-MS system (QTrap 5500 MS (AB Sciex,
Foster City, CA, USA) with ExpressHT Ultra LC (Eksigent Div., AB Sciex, Foster City, CA,
USA). We added supernatant (20 μl) of centrifuged TCA deproteinized plasma to a 0.1 N
hydrochloric acid containing internal standard (20 μl) of a stable isotopomer [D8-valine,
D5-proline]. We derivatized internal standard containing samples and di-peptide external
standards with 9-Fluorenylmethoxycarbonyl (Fmoc), neutralized and injected 160 nL of the
solution on a micro LC column 0.5 x 100 mm HALO C18, 2.7 um, 90A pores at 35°C. We
eluted the analytes with a segmentally linear gradient from 35% to 85% acetonitrile in water
supplemented with ammonium acetate to 10 μM and 5% isopropanol. We detected by electro-
spray triple quadrupole tandem mass spectrometry in multiple reactions monitoring mode.
For concentration calculations of di-peptides, we normalized MS signals of the samples and the
external standards with their internal standard. We determined di-peptide concentrations with
the calibration curve of the external standards.
We determined plasma PAH concentrations with a standard enzymatic method on an auto-
matic spectrophotometric analyzer (Cobas Mira, Hoffmann-La Roche, Basel, Switzerland) as
described [22,30–32]. In brief, we measured plasma PAH concentration at 465 nm using Ehr-
lich’s reagent: 1 g p-dimethylaminobenzaldehyde (Merck, Darmstadt, Germany), 35 ml alcohol
96%, 4 ml TCA 2N, 61 ml water (bi-distilled) and a solution of 35% alcohol.
Calculations
Systemic pharmacokinetics. Using a 1-compartment model [25] we determined in study
1, absorption half-life (t½,a;min), time to maximum plasma concentration (tmax;min), maxi-
mum plasma concentration (Cmax;nM), elimination half-life (t½,e;min) and systemic absolute
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bioavailability (fAbs;%). For study 2, we used a non-compartmental analysis calculate AUCs of
the arterial XPP time curves from 0 to 360 min (nmol/lmin). We calculated the systemic bio-
availability relative to regular, basal meal using the following equation:
fRel ¼
AUCBasal  DTest
AUCTest  DBasal
 100%
where fRel = the bioavailability for a administered XPP from a meal relative to Basal (%),
AUCBasal = the AUC for Basal (nmol/lmin), DTest = the dose of an XPP in the meal (nmol),
AUCTest = the AUC for the meal (nmol/lmin), DBasal = the XPP dose of Basal (nmol).
XPP organ fluxes. We measured plasma flow, necessary to calculate amino acid fluxes
across organs. We calculated PDV fluxes of IPP, LPP and VPP by portal-arterial XPP concen-
tration difference times portal plasma flow, liver fluxes by subtracting PDV flux from splanch-
nic flux (hepatic-arterial difference liver plasma flow) and renal flux by renal plasma flow
times renal-arterial XPP concentration difference [22,28,31,32,35]. We expressed organ flux as
pmol/kg body weight/min and a positive flux is net release of XPP and negative flux net
uptake.
We calculated total net release or uptake (= organ net balance) of XPP across an organ from
the area under curve of the respective organ flux time course. We expressed total net balance as
pmol/kg bodyweight. For the PDV, the portal bioavailability is the total net balance as fraction
dose of IPP, LPP or VPP in the test mixtures/meals. We calculated the free available XPP in the
test mixtures of study 1 or test meals in study 2 from information, made available by the
manufacturer.
Statistical procedures
We used Prism 6 (Graphpad Software, La Jolla, CA, USA) for statistics, expressed the results as
means ± SEM and set the level of significance on p<0.05 and tendencies are defined as p<0.01.
We tested the data for normality and used the Wilcoxon test to determine if means are differ-
ent from zero.
Comparisons between matrixes and mean XPP responses where done with two-way
ANOVA. When appropriate, followed by post-hoc test (Sidak’s, Dunnett’s, Fisher’s LSD or
Wilcoxon Signed Rank test as indicated in tables and figures) for planned physiological rele-
vant multiple comparison.
We compared the means of two groups with unpaired t-test or Wilcoxon matched pairs
signed rank test, means of more than three groups with One-way repeated measures ANOVA.
When appropriate, followed by a post-hoc test (Dunnett’s) for planned physiological relevant
multiple comparison.
We compared means of groups in the time courses with two-way ANOVA test, mixed
model: repeated measurements for time (fixed effect) but not for test mixtures, for planned
physiological relevant comparisons.
Results
Effect of a protein matrix on systemic bioavailability and
pharmacokinetics of XPP peptides
Systemic (= arterial) concentrations of XPP in time (Fig 1) showed no measurable baseline/
post-absorptive endogenous XPP (Control group, tested with Wilcoxon). The XPP concentra-
tions in the CasH groups were not back to baseline at 90 min post-prandial (one-way ANOVA
with Dunnett’s post-hoc test: IPP p<0.002; LPP p<0.001; VPP p<0.05). The calculated
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systemic absolute bioavailability (fabs (%) = fraction dose absorbed, Table 3) was increased in
the protein based CasH group (IPP: 4.7 times, p<0.0004; LPP: 2.5 times, p<0.002; VPP: 121
times, p<0.0001). The spiked CasH group (CasH+XPP) showed lower systemic bioavailability
for VPP (65 times, p<0.0001) in comparison to CasH. There was a delay in the time to maxi-
mum XPP plasma concentration (tmax) with the CasH groups compared to the XPP test mix-
ture (12 min, p<0.0001, Wilcoxon matched pairs signed rank test). The calculated absorption
Fig 1. Systemic levels of XPP peptides—Effect of protein matrix. Post-prandial arterial concentrations
after intra-gastric administration of control salt solution (Control), synthetic XPP’s (XPP), casein hydrolysate
rich in XPP (CasH) and spiked CasH (CasH + XPP). A: Isoleucine-proline-proline (IPP). B: Leucine-proline-
proline (LPP). C: Valine-proline-proline (VPP). Respective number of observations for Control, XPP, CasH
and CasH +XPP are for graph A: n = 9, 10, 9 and 10; graph B: n = 10, 10, 9 and 10; graph C: n = 8, 10, 9 and
10. Values are mean ± SEM. Statistics: repeated measures two-way ANOVA, mixed model, planned
comparisons. All curves are significantly different from the XPPmixture: effect test mixture p<0.001; effect
time p<0.001; interaction p<0.001.
doi:10.1371/journal.pone.0130638.g001
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half-life (t½,a) and elimination half-life (t½,e) was delayed significantly in CasH groups (resp. 6
min and 20 min, p<0.0001, Wilcoxon matched pairs signed rank test). Plasma concentrations
of the dipeptides LP, IP, VP and PP in the post-prandial period, measured in a limited set of
samples, were in the range of 1–7 μM, compared to 1–30 nM for XPP’s in this sample set
(S1 Table. Dipeptide/tripeptide ratio—Study 1.).
Effect of meal matrix on portal availability of XPP peptides
PDV fluxes showed a net release of all XPP after intra gastric administration of XPP in different
matrixes (Fig 2). We observed no endogenous production of XPP by the PDV. The patterns of
the curves were comparable for IPP, LPP and VPP. No differences in PDV plasma flows were
observed (S2 Table. Plasma flows—Study 1.). The single dose water-based synthetic XPP
matrix, showed comparable portal availability for IPP, LPP and VPP, with an average of
0.08 ± 0.01% of the intake (Table 4). The portal availability was higher in a protein (CasH)
matrix than in water-based XPP matrix, but different between IPP, LPP and VPP (IPP 3.1
times, p = 0.026; LPP 1.8 times, p = 0.23; VPP 83 times, p<0.0001). For VPP, the spiked CasH
showed a different portal availability in comparing to the non-spiked CasH matrix (0.05 times
of CasH, p<0.0001). To understand the significant XPP effect and spike effect, data were fur-
ther analyzed, by expressing the data as % of theoretically intake of XPP (S3 Table. Theoretical
Table 3. Systemic bioavailability and pharmacokinetics of XPP peptides—Effect of a protein matrix.
p-value2
Parameter Matrix Group IPP LPP VPP Matrix/Spike effect XPP effect Inter-action
fabs (%) Water-based XPP1 0.08±0.01 0.06±0.01 0.07±0.02 <0.0001 <0.0001 <0.0001
protein CasH 0.38±0.05* 0.15±0.03* 8.49±0.69* <0.0001 <0.0001 <0.0001
CasH+XPP 0.26±0.06# 0.16±0.04 0.13±0.78#
t½,a (min) Water-based XPP1 3.3±0.5 2.0±0.5 4.6±1.1 0.003 0.687 0.581
protein CasH 11.2±3.3 7.8±2.3 8.5±2.5 0.978 0.789 0.697
CasH+XPP 7.8±3.6 8.0±2.6 10.5±2.8
tmax (min) Water-based XPP1 8.6±0.6 7.1±0.7 8.9±0.6 <0.0001 0.628 0.805
protein CasH 22±5 19±2 19±2 0.775 0.771 0.818
CasH+XPP 19±5 19±3 20±3
Cmax (nM) Water-based XPP1 12±3 11±3 9±2 0.026 0.823 0.762
protein CasH 16±3 17±3 16±3 0.022 0.905 0.744
CasH+XPP 25±3 21±3 21±3
t½,e (min) Water-based XPP1 9.3±1.1 15±4 12±6 <0.0001 0.590 0.192
protein CasH 39±5 31±11 27±4 0.970 0.236 0.462
CasH+XPP 36±6 42±12 23±4
Pharmacokinetic parameters derived from the systemic response of an intra gastric bolus administrated of the tri-peptides isoleucine-proline-proline (IPP),
leucine-proline-proline (LPP), valine-proline-proline (VPP) in water-based matrix (synthetic XPP) or in a protein matrix (casein hydrolysate rich in XPP:
CasH). fabs (%): systemic absolute bioavailability, t½,a: absorption half-life, tmax: time to maximum plasma concentration, Cmax: maximum plasma
concentration, t½,e: elimination half-life. Parameters calculated with a 1-compartment model. Values are means ± SEM. For fabs n = 8. For other
parameters XPP: n = 10; CasH: n = 10; CasH+XPP: n = 9. Significance: p<0.05.
1): Data XPP group from the present study 1, are published in van der Pijl et al. [25].
2): Significance for comparison of water-based matrix (XPP) with protein matrix (CasH). Or significance for comparison between XPP spiked (CasH+XPP)
and non-spiked protein matrix (CasH): Two-way ANOVA. When appropriate, a post-hoc unpaired t-test is done:
*): p<0.05 significance for comparison IPP, LPP or VPP of XPP relative to CasH.
#): p<0.05 significance for comparison IPP, LPP or VPP of CasH relative to CasH+ XPP.
doi:10.1371/journal.pone.0130638.t003
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Fig 2. Portal Drained Viscera fluxes of XPP—Effect of a protein matrix. Post-prandial portal drained
viscera (PDV) fluxes after intra-gastric administration of tri-peptide (XPP) mixtures: control salt solution
(Control), synthetic XPP’s (XPP), casein hydrolyte rich in XPP (CasH) or spiked CasH (CasH + XPP). A:
Isoleucine-proline-proline (IPP). B: Leucine-proline-proline (LPP). C: Valine-proline-proline (VPP).
Respective number of observations for Control, XPP, CasH and CasH +XPP are for graph A: n = 6, 9, 8 and
9; graph B: n = 6, 10, 9 and 9; graph C: n = 5, 9, 9 and 9. Values are mean ± SEM. Positive values is net
release, negative values is net uptake. Statistics: repeated measures two-way ANOVA, mixed model,
planned comparisons. All curves are significantly different from the XPPmixture: effect test mixture p<0.01;
effect time p<0.01; interaction p<0.01
doi:10.1371/journal.pone.0130638.g002
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XPP intake and their portal availability—Study 1.), considering the tri-peptide sequences in the
source of the CasH: amino acid sequence of bovine k and β casein (www.genome.jp; CASB-
BOVIN, CASK-BOVIN). No spike effect of VPP was observed when corrected of potential non
free available VPP sequences in the CasH. With this correction we determined that on average
the portal availability was 1.8 times higher in the protein matrix (XPP 0.08 ± 0.01 vs CasH
0.14 ± 0.02, two-way ANOVA, matrix effect, p = 0.004). Further analyses of the PDV flux
curves showed an increase of 2.1 times of the portal release half-life (Table 4) in the protein
matrix in comparison to the water-based matrix (XPP: 15 ± 2 min vs CasH: 33 ± 3 min, two-
way ANOVA, matrix effect<0.0001).
Multiple organ interactions of XPP peptides
In Study 1, we determined the XPP fluxes across multiple organs, to understand more about
the influence of different organs on the systemic availability. We found no effect of the matrixes
on the plasma flows of PDV, liver and kidneys (S4 Table). In the post-absorptive Control
group, total net balances of XPP were not different from zero (Fig 3). Post-prandial balances
showed a net release of XPP by the PDV, followed by a partial uptake by the liver, resulting in
net release of XPP by the splanchnic area. Systemic available XPP are in part, taken up by the
kidneys.
Effect of meal matrix on the systemic availability of XPP peptides
In study 2, we compared XPP responses between a protein and a meal matrix and the potential
effects of different macro-nutrients in a meal matrix. With the Basal meal matrix, the systemic
Table 4. Portal bioavailability and release half-life of XPP peptides—Effect of a protein matrix.
p-value1
Parameter Matrix Group IPP LPP VPP Matrix/Spike
effect
XPP
effect
Inter-
action
PDV total net balance (% of
intake)
Water-
based
XPP 0.08±0.03 0.09
±0.03
0.07±0.02 <0.0001 <0.0001 <0.0001
protein CasH 0.25
±0.04*
0.17
±0.03
5.81
±0.98*
<0.0001 <0.0001 <0.0001
CasH
+XPP
0.19±0.03 0.16
±0.03
0.28
±0.05#
t½,r (min) Water-
based
XPP 11±1 16±5 18±5 <0.0001 0.921 0.556
protein CasH 34±4§ 32±3§ 32±5§ 0.297 0.678 0.739
CasH
+XPP
32±3 29±3 34±4
Portal bioavailability, measured as post-prandial total net release to the portal system (PDV total net balance), and time when 50% of total portal tri-
peptide net release occurred (t½,r) after an intra gastric bolus administrated of the tri-peptides isoleucine-proline-proline (IPP), leucine-proline-proline
(LPP), valine-proline-proline (VPP) in a water-based matrix (synthetic XPP) or in a protein matrix (casein hydrolysate rich in XPP: CasH). Values are
means ± SEM; XPP: n = 8; CasH: n = 8; CasH+XPP: n = 9. Significance: p<0.05.
1): significance for comparison of water-based matrix (XPP) with protein matrix (CasH). Or significance for comparison between XPP spiked (CasH+XPP)
and non-spiked protein matrix (CasH): Two-way ANOVA. When appropiate post-hoc unpaired t-test is done:
*): p<0.05 significance for comparison IPP, LPP or VPP of water-based matrix (XPP) relative to protein matrix (CasH).
#): p<0.05 significance for comparison IPP, LPP or VPP of protein matrix (CasH) relative to spiked protein matrix (CasH+ XPP). When appropriate
post-hoc Fisher’s LSD is done:
§): p<0.05 significance for comparison IPP, LPP or VPP of waterbased matrix (XPP) relative to protein matrix (CasH).
doi:10.1371/journal.pone.0130638.t004
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Fig 3. Organ Total Net balances of XPP peptides. Study 1. Post-prandial total net balances across organs
over 90 min experimental period after intra-gastric administration of tri-peptide (XPP) mixtures: a synthetic
dose of XPP (XPP), XPP containing casein hydrolyte (CasH) and spiked CasH (CasH + XPP). Organs: portal
drained viscera (PDV), Liver, Splanchnic area (SPL), Kidneys. Positive balance is net release by an organ.
Negative balance is net uptake by an organ. Values are mean ± SEM. Statistics: unpaired t-test for
comparison of net balances of natural occurring XPP vs administrated XPP (Control vs XPP), water-based vs
protein matrix (XPP vs CasH), and for comparison protein matrixes with vs without XPP spike (CasH vs CasH
+XPP). Hooks: significance p<0.05. dotted hooks: tendency p<0.10.
doi:10.1371/journal.pone.0130638.g003
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availabilities of XPP’s were 1.2 times (p = 0.019, Wilcoxon rank test) increased over a post-
prandial period of six hours in comparison to the protein matrix CasH2 (Table 5). The low
quality protein and fiber were the macronutrients that increased the XPP systemic availability
in a meal further with resp. 1.5 and 1.4 times in comparison to the Basal meal. (Two-way
ANOVA with post-hoc Dunnett’s test; macronutrient effect: resp. p = 0.0003 and p = 0.0009).
Effect of a meal matrix on portal availability of XPP peptide
Expressed as the fraction dose of total PDV net balance over the experimental period of six
hours, the portal availability was increased with an average 1.8 times (56±7% of Basal, two-way
ANOVA, matrix effect,<0.0001) if the XPP containing CasH was given with a complete meal
(Table 6). In contrast with the systemic bioavailability, we did not observe differences between
the basal and the other meals and in PDV plasma flows (S4 Table. PDV Plasma flows—Study
2.). Further analysis of the PDV flux curves showed an increase of 2.6 times of the portal release
half-life (Table 7) in the meal matrix in comparison to the protein matrix (CasH2: 47 ± 5 min;
Basal: 122 ± 11 min; two-way ANOVA, matrix effect<0.0001). Also, the portal release half-life
was reduced in a low quality protein meal 1.5 times, and increased 1.3 times in a high fat con-
taining meal (LQprot: 80 ± 7; hFat: 163±10; two-way ANOVA with post-hoc Dunnett’s multi-
ple comparison, macronutrient effect resp. p = 0.009 and p = 0.014).
Discussion
Systemic bioavailability of orally ingested lacto-tri-peptides (XPP) may affect their potential
bioactive impact. We hypothesized that macronutrients, especially protein, are able to change
systemic availability and that differences in absorption kinetics of the XPP in the splanchnic
region cause these changes.
Does a protein matrix improve bioavailability? In a post-absorptive state, we do not detect
XPP in plasma above the limit of detection and thus any measurable XPP most likely originates
from the meal (Fig 1). The calculated systemic bioavailability of XPP in the presence of a pro-
tein matrix (casein hydrolysate) does improve for all XPP, but not in the same proportion
Table 5. Systemic bioavailability of XPP peptides—Effect of a meal matrix.
Statistics
Matrix Group IPP (%) LPP (%) VPP (%) Matrix/diet effect XPP effect Interaction Macronutrient effect
protein CasH2 84±11 86±8 84±14 p1 0.010 0.986 0.986
meal Basal 100 100 100 p2 0.0001 0.832 0.990
LQprot 160±22 152±15 143±19 p3 0.0003
hCHO 105±8 109±11 100±11 p3 0.987
hFat 112±14 115±16 116±18 p3 0.628
Fiber 126±18 152±29 140±23 p3 0.009
Systemic absolute bioavailability derived from the systemic response after an intra gastric bolus administrated of the tri-peptides isoleucine-proline-proline
(IPP), leucine-proline-proline (LPP), valine-proline-proline (VPP) in a protein matrix (casein hydrolysate rich in XPP: CasH2) or in CasH containing meal
matrix (Basal). Or in meals with different amount of macronutrients: low quality protein (LQprot), high amount of carbohydrates (hCHO + CasH), high
amount of fat (hFat) or with fiber (Fiber). Systemic bioavailability is expressed relative to Basal in %. Values are mean ± SEM. Basal, hCHO: n = 10; hFat,
LQprot: n = 9; CasH2: n = 8. Significance: p<0.05.
p1: significance for comparison of protein matrix with meal matrix: Two-way ANOVA.
p2: significance for comparison meal matrixes: Two-way ANOVA.
p3: significance for macronutrient effect (LQprot, hCHO, hFat, or Fiber meal vs Basal): post-hoc Dunnett’s multiple comparison test.
doi:10.1371/journal.pone.0130638.t005
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(Table 3, IPP: 4.7 times; LPP: 2.5 times; VPP: 121 times). The calculated systemic bioavailability
pattern reflects the pattern of the measured portal bioavailability (Table 4), albeit underesti-
mated because of delayed and prolonged systemic bioavailability after 90 min. This indicates
that the systemic availability mainly relates to the portal availability of XPP. A protein matrix
improves the portal bioavailability of all XPP by prolonging gut absorption (Fig 2, Table 4), but
also not in the same proportion. The spiked protein matrix indicates that the relative large
improvement of VPP bioavailability was not matrix related.
A point to consider is whether the presence of not-freely- available XPP’s (XPP’s bound in
longer peptides (“encrypted”) in the casein hydrolyte affected our results. The portal bioavail-
ability of XPP in a water-based matrix is comparable between the XPP. This in contrast with
XPP in the protein matrix. We assume that this is related to encrypted VPP in the protein
Table 6. Portal bioavailability of XPP peptides—Effect of a meal matrix.
Statistics
Matrix group IPP (%) LPP (%) VPP (%) Matrix/diet effect XPP effect Interaction
protein CasH2 54±12* 55±13* 59±15* p1 <0.0001 0.948 0.948
meal Basal 100 100 100 p2 0.859 0.872 0.999
LQprot 99±9 100±12 109±10
hCHO 107±25 116±31 113±28
hFat 95±15 79±15 106±23
Fiber 99±29 113±54 106±32
Portal bioavailability derived from the systemic response after an intra gastric bolus administrated of the tri-peptides isoleucine-proline-proline (IPP),
leucine-proline-proline (LPP), valine-proline-proline (VPP) in a protein matrix (casein hydrolysate rich in XPP: CasH2) or in CasH containing meal matrix
(Basal). Or in meals with different amount of macronutrients: low quality protein (LQprot), high amount of carbohydrates (hCHO + CasH), high amount of
fat (hFat) or with fiber (Fiber). Portal bioavailability is expressed relative to Basal in %. Values are mean ± SEM. Basal: n = 10; hFat, LQprot, hCHO: n = 9;
CasH2: n = 8. Significance: p<0.05.
p1: significance for comparison of protein matrix with meal matrix: Two-way ANOVA.
*): p<0.05 significance for comparison IPP, LPP or VPP portal availability of CasH2 relative to Basal with post-hoc Wilcoxon signed Rank test.
p2: significance for comparison meal matrixes: Two-way ANOVA.
doi:10.1371/journal.pone.0130638.t006
Table 7. Portal release half-life of XPP peptides—Effect of a meal matrix.
Statistics
Matrix group IPP (min) LPP (min) VPP (min) Matrix/diet effect XPP effect Interaction Macronutrient effect
protein CasH2 47±7* 49±9* 45±7* p1 <0.0001 0.977 0.916
meal Basal 125±19 116±21 125±21 p2 <0.0001 0.797 0.997
LQprot 85±12 76±13 78±13 p3 0.009
hCHO 112±16 113±21 122±19 p3 0.970
hFat 166±17 168±15 155±22 p3 0.014
Fiber 136±10 114±19 129±18 p3 0.997
Time after administration when 50% of total portal tri-peptide release (net balance) has occurred (t½,r in min). Values are mean ± SEM. (Basal, LQprot,
hFat: n = 10; CasH2, hCHO: n = 9; hCHO: n = 7) Significance: p<0.05.
p1: significance for comparison of comparing protein matrix with meal matrix: Two-way ANOVA.
*): p<0.05 significance for comparison IPP, LPP or VPP portal release half-life of CasH2 relative to Basal with post-hoc Sidak’s multiple comparison test.
p2: significance for comparison meal matrixes: Two-way ANOVA.
p3: significance for macronutrient effect (LQprot, hCHO, hFat, or Fiber meal vs Basal) with post-hoc Dunnett’s multiple comparison test.
doi:10.1371/journal.pone.0130638.t007
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source of CasH. The source of CasH is κ- and β-casein and these proteins have lacto-tri-
peptides encrypted [36], that are liberated during an enzymatic hydrolysis process by the man-
ufacturer. It is likely that still encrypted XPP’s in the larger peptides of the hydrolyte are liber-
ated during the digestive process in the pig [1]. These XPP also will contribute to the intestinal
net balance. More in detail, the current enzymatic hydrolysis process (information of the man-
ufacturer) liberates mainly VVVPP-peptides and only a small amount of VPP. Therefore, we
conclude by theoretically calculations (S3 Table. Theoretical XPP intake and their portal avail-
ability—Study 1.) that the high fraction dose of VPP release in comparison to IPP and LPP
relates to this mechanism. We found that the average improvement of XPP portal bioavailabil-
ity by a protein matrix is 1.8 times, albeit underestimated because of prolonged portal bioavail-
ability after 90 min.
The prolonged XPP net absorption from the protein meal could be the result of processes
such as stomach emptying, digestion and competition between the absorption of XPP and
amino acids on the lumen side. Some of the digested peptides in the dietary proteins are resis-
tant to further digestion because of the type of amino acids bonds to other amino acids like for
proline-containing peptides [2,37]. Trans-epithelial transport in the intestinal tract to the por-
tal system of XPP can occur in three different ways: para-cellular, trans-cytotic or via peptide
transport system via the proton-dependent transporter, PepT1 [24,38]. In vitromeasurements
of trans-epithelial flux of VPP across a Caco-2 cell monolayer [38] indicated that the para-cel-
lular route is the most likely route for intact VPP. Because absorption of XPP in hydrolysates
in healthy pigs is not more limited than the same amount of single amino acids [39,40], we
think that delayed stomach emptying caused the prolonged absorption.
The systemic pharmacokinetics suggests that the improved bioavailability mainly is caused
by delay in absorption and prolonged elimination. Systemic bioavailability is not only depen-
dent on the portal availability but also depending on the elimination from systemic plasma to
other organs. We found hepatic and renal XPP uptake (Fig 3), but uptake is approx. 75% of
total PDV release. This means that other, not measured organs, also take up XPP [3]. Uptake
means that XPP is available for potential ACE-inhibition targets in organs like the vascular
endothelial cells or absorptive epithelial cells (kidney) [3,4], but also that XPP peptides are
eliminated from the systemic by intracellular breakdown to amino acids by peptidases, or
excretion to urine in the kidney. Further research in intra-organ kinetics is needed to quantify
those processes.
Foltz et al [41] determined in vitro that also di-peptides with a C-terminal proline residue
has ACE inhibitory effects. In a pilot analysis, we found that the plasma concentration of
related di-peptides is 20–400 times higher than that of XPP (S1 Table. Dipeptide/tripeptide
ratio—Study 1.). This suggest that food-derived lacto-di-peptides have a potential synergetic
role in the bioactivity, but that need to be determined in another experimental design.
Does a meal improve XPP systemic availability by improved portal availability? Systemic
availability increased by a meal matrix but only by 20% (Table 5) in comparison to a protein
matrix. Portal availability increased 80% by a meal matrix (Table 6). Higher portal release half-
life (Table 7) indicates prolonged absorption and release to the portal system by the gut in a
meal matrix.
Why does a complete meal matrix improve portal XPP availability? First, it is likely that the
speed of absorption of regular meals is slower than a single dose of CasH and that this prolongs
absorption of peptides. Fat is known to delays gastric emptying [42]. In contrast, we did not
observe any improvement of the portal bioavailability with the meals that contain a high
amount of fat. Secondly, the small intestine is the interface between the gut lumen and the rest
of the body and therefore controls the degree and rate of transport of amino acids coming from
the meal via the portal vein [29]. It could be that competition of amino acids trans-epithelial
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transport plays a role, because the amount of amino acids from digested proteins (3.05 g/kg
bodyweight, Whey and Soy isolate together with CasH) is higher in the complete meals as com-
pared to a single dose of CasH (0.73 g/kg bodyweight). We think however that this is also
unlikely as the absolute amount of protein given in the test is still relative low (30% of restricted
daily intake), considering the potential absorption capacity of the gut of a pig [43]. Therefore,
we need to consider stimulated gut metabolism after the meal in comparison to a protein mix-
ture alone [19]. We found that adding carbohydrates leads to higher insulin levels, it stimulates
increased protein synthesis and reduced protein breakdown, leading to more gut tissue anabo-
lism [44,45]. Therefore, we think that reduced intracellular intestinal protein breakdown is
related to the reduced XPP breakdown and thus higher transport to the portal vein. We there-
fore think that the gut anabolic response in the meals is the most likely mechanism to a higher
portal bioavailability. Further research is needed to confirm our hypothesis.
What is the influence of the macronutrients on the systemic availability? Although total
portal release of XPP is comparable during the experimental period (Table 6), systemic avail-
ability is higher with the low quality protein meal and high fiber meal (Table 5). Additionally
in contrast, low protein decreases and high fat increases the portal release half-life of XPP
(Table 7), suggesting that increased systemic availability can not be related to differences in
intestinal XPP absorption, but suggests that other organs/metabolism are involved. For
instance, we observed that soy protein leads to less anabolism [17,46]. This means that organs
take up less amino acids and probably also less XPP from the systemic circulation for protein
anabolism, resulting in higher systemic availability of XPP. We have no good explanation for
the observation of the improved XPP systemic availability by high fiber meal. Fiber has multi-
ple health benefits but limited info is available about a direct relation between fiber and pep-
tide/protein metabolism [47].
Conclusion
Quantitative measurements of trans-organ availability/kinetics provide more insight of the
behavior of food-derived C-terminal lacto-tri-peptides like XPP. The present study showed
that XPP in a protein matrix have a prolonged portal bioavailability. In a meal with all macro-
nutrients present, XPP are more available albeit at a low percentage (0.2–0.3%). The digestion
rate of the meal, the quality of protein, and fiber contents, mainly determine systemic XPP bio-
availability after a meal.
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